04/17/24 04:46 pm HOUSE RESEARCH EK/MV H4571A3

...... moves to amend H.F. No. 4571, the delete everything amendment

1.1

1.2	(H4571DE2), as follows:
1.3	Page 64, delete lines 9 to 26 and insert:
1.4	"(2) oral buprenorphine to treat a substance use disorder;
1.5	(3) outpatient mental health treatment or outpatient substance use disorder treatment,
1.6	except for treatment which is: (i) a medication; and (ii) not otherwise listed in this
1.7	subdivision. Prior authorizations required for medications used for outpatient mental health
1.8	treatment or outpatient substance use disorder treatment, and not otherwise listed in this
1.9	subdivision, must be processed according to section 62M.05, subdivision 3b, for initial
1.10	determinations, and according to section 62M.06, subdivision 2, for appeals;
1.11	(4) antineoplastic cancer treatment that is consistent with guidelines of the National
1.12	Comprehensive Cancer Network, except for treatment which is: (i) a medication; and (ii)
1.13	not otherwise listed in this subdivision. Prior authorizations required for medications used
1.14	for antineoplastic cancer treatment, and not otherwise listed in this subdivision, must be
1.15	processed according to section 62M.05, subdivision 3b, for initial determinations, and
1.16	according to section 62M.06, subdivision 2, for appeals;
1.17	(5) services that currently have a rating of A or B from the United States Preventive
1.18	Services Task Force, immunizations recommended by the Advisory Committee on
1.19	Immunization Practices of the Centers for Disease Control and Prevention, or preventive
1.20	services and screenings provided to women as described in Code of Federal Regulations,
1.21	title 45, section 147.130;
1.22	(6) pediatric hospice services provided by a hospice provider licensed under sections
1.23	144A.75 to 144A.755; and
1.24	(7) treatment delivered through a neonatal abstinence program operated by pediatric

pain or palliative care subspecialists.

1.25

04/17/24 04:46 pm	HOUSE RESEARCH	EK/MV	H4571A3
U4/1 ///4 U4·46 nm	HUIINE KENEAKUH	FK/IVIV	H43/IA3

2.1	Clauses (2) to (7) are effective January 1, 2026, and apply to health benefit plans offered,
2.2	sold, issued, or renewed on or after that date."
2.3	Page 65, delete section 29
2.4	Page 68, line 25, delete "Subdivision 1. Annual report; contents."
2.5	Page 68, line 29, delete ", sorted by the categories of services listed in subdivision 2"
2.6	Page 69, line 12, delete everything after "determinations"
2.7	Page 69, line 13, delete "in subdivision 2"
2.8	Page 69, delete lines 19 to 28
2.9	Page 70, after line 11, insert:
2 10	"See Minnesote Statutes 2022 section 620 1941 subdivision 2 is amonded to made
2.10	"Sec Minnesota Statutes 2022, section 62Q.1841, subdivision 2, is amended to read:
2.11	Subd. 2. Prohibition on use of <u>prior authorization or step therapy protocols.</u> A health
2.12	plan that provides coverage for the treatment of stage four advanced metastatic cancer or
2.13	associated conditions must not limit or exclude coverage for a drug approved by the United
2.14	States Food and Drug Administration that is on the health plan's prescription drug formulary
2.15	by mandating that an enrollee with stage four advanced metastatic cancer or associated
2.16	conditions obtain a prior authorization or follow a step therapy protocol if the use of the
2.17	approved drug is consistent with:
2.18	(1) a United States Food and Drug Administration-approved indication; and
2.19	(2) a clinical practice guideline published by the National Comprehensive Care Network.
2.20	EFFECTIVE DATE. This section is effective January 1, 2025, and applies to health
2.21	plans offered, sold, issued, or renewed on or after that date."
2.22	Renumber the sections in sequence and correct the internal references
2.23	Amend the title accordingly

Sec. . 2